"Eiither in oncology or beyond" dosing app17 Jul 2025 06:45
Physiomics plc expands partnership with DoseMe 📣
We are very excited to announce our expanded partnership with DoseMe, a leading US-based provider of model-informed precision dosing (MIPD) software.
This update includes:
👉 Implementation of our Personalised Dosing Software for G-CSF treatment onto the DoseMeRx platform, with the tool now available to clinicians and health care providers on a research-only basis.
👉 Intention to collaborate on new dosing software tools beyond GCSF and Docetaxel.
This marks a significant milestone in our collaboration with DoseMe, combining DoseMe's scalable platform with our deep expertise in modelling to work together to advance more precise, patient-centred dosing solutions for oncology and beyond.
🗨️ Dr Peter Sargent: “This not only marks a positive step towards the eventual commercialisation of our current Personalised Dosing Software, but also our ambition to apply our extensive modelling expertise into the development of new dosing software, either in oncology or beyond.”